Navigation Links
Data Related to Chimerix's Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings
Date:2/4/2013

RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing antivirals in areas of high unmet medical need, today announced that three abstracts related to the broad-spectrum antiviral compound CMX001 will be presented at the BMT Tandem Meetings being held February 13-17 in Salt Lake City.  The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT).  

Chimerix's presentations on CMX001 address the emerging safety profile of the compound and early clinical data on its activity against BK virus, and will be presented on Saturday, February 16 from 7:00 am to 5:00 pm MT:

Renal Safety of Broad Spectrum Antiviral CMX001 in the Prevention of CMV Infection Post‐Allogeneic Hematopoietic Cell Transplantation (HCT)

Monitoring Changes in Serum Albumin (SA) Concentrations as an Early and Objective Indicator of Potential CMX001‐Associated Gastrointestinal (GI) Adverse Drug Effects  

BK Virus‐Associated Nephropathy (BKVN), an Under‐Recognized Cause of Renal Dysfunction in Severely Immunosuppressed Hematopoietic Stem Cell Transplant (HSCT) Patients: Report of 5 Cases of BKVN and the Potential Role of CMX001 for Treatment  

For more information, please see the BMT Tandem Meetings website:  http://www.asbmt.org/displaycommon.cfm?an=3.

About Chimerix and CMX001
Chimerix is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need.  The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens. 

Chimerix's lead product candidate, CMX001, is a broad spectrum, oral nucleotide analog lipid-conjugate that blocks replication of double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus.  CMX001 has completed Phase 2 clinical development for the prevention of CMV in hematopoietic stem cell transplant (HSCT) recipients.  Chimerix is also conducting a Phase 2 study in HSCT recipients which is evaluating CMX001 as a preemptive therapy for AdV disease, an often-fatal infection which has no approved therapies.  Since 2009, Chimerix has made CMX001 available under expanded access regulations to over 80 transplant centers worldwide for the treatment of over 430 patients with life-threatening dsDNA viral infections.  Chimerix anticipates initiating SUPPRESS, its Phase 3 study of CMX001 for the prevention of CMV infection in adults undergoing HSCT, in 2013.   

Chimerix is also developing CMX001 as a potential medical countermeasure against smallpox under a contract from the Biomedical Advanced Research and Development Authority (BARDA). 

Chimerix's second product candidate, CMX157, an oral nucleotide analog lipid-conjugate in Phase 1 development for the treatment of HIV infection, was licensed to Merck in July 2012.   


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. In Preventing Diabetes-Related Heart Disease, Blood Pressure and Cholesterol Targets are Higher Priorities than Blood Sugar
2. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
3. Atonomics Achieves Significant Milestone Related to Performance Data for Troponin I Assay Triggering Scheduled Payments From Beckman Coulter
4. Exercise Rate Related to Improvements in Parkinsons Disease
5. Analysis Finds Improvements in Health-Related Quality of Life for Hereditary Angioedema Patients Treated with C1-Inhibitor
6. RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer
7. New "15 Every Hour" Campaign Spreads the Word on the Devastating Impact of AFib-Related Stroke
8. Call for Submissions: ICAP Patent Brokerage Announces Expansion of Life Sciences Practice and Increased Buyer Interest in Related Intellectual Property
9. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
10. PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract
11. UBM Canon, the Global MedTech Authority, Partners with the World Medical Device Organization, WMDO, to Provide Medical Device Companies with Industry-Related Online Training Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... , July 13, 2017 RK Logistics Group, ... of Pharmacy certification for its Fremont, CA ... solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont Innovation ... to provide such a powerful resource to the hundreds of ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... ... Community for Addiction Recovery (CCAR) will host a second Multiple Pathways of Recovery ... Punta Gorda, Florida. The conference, born from CCAR’s foundational principle – a belief ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... provider of education and training standards for healthcare treatment providers, offers healthcare ... Certification: the iaedp™ Core Curriculum. , Presented as either online or as ...
(Date:7/23/2017)... ... ... Scientists from the University of Exeter reported this month results ... to a medium-paced run for pre-menopausal women, or a slow jog for post-menopausal women, ... care, I understand the importance exercise can play on improving bone health. Although it ...
(Date:7/23/2017)... ONTARIO, CANADA (PRWEB) , ... July 23, 2017 , ... ... a way to gain that elusive college scholarship or even go on to the ... Medicine’s Annual Meeting in Toronto, Canada today say “not so fast.” , ...
(Date:7/23/2017)... , ... July 23, 2017 , ... “I Am Not ... from the mountains who could barely read and write and a brokenhearted young soldier ... disillusioned. The coming of age novel about the power of simple faith is the ...
Breaking Medicine News(10 mins):